|
Market Closed -
Nasdaq
16:00:00 2026-08-21 EDT
|
5-day change | 1st Jan Change | ||
| 0.4010 USD | +5.50% |
|
+0.25% | -70.07% |
| 08-07 | Soligenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 06-08 | Soligenix Applies for Vaccine Development Funding for Bundibugyo Ebola Vaccine | CI |
Company Valuation: Soligenix, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 28.31 | 19.54 | 7.858 | 6.763 | 13.52 | 8.728 | - | - |
| Change | - | -30.98% | -59.78% | -13.94% | 99.84% | -35.42% | - | - |
| Enterprise Value (EV) | 28.31 | 19.54 | 7.858 | 6.763 | 13.52 | 8.728 | 8.728 | 8.728 |
| Change | - | -30.98% | -59.78% | -13.94% | 99.84% | -35.42% | 0% | 0% |
| P/E | -2.13x | -1.41x | -0.96x | -0.54x | -0.63x | -0.73x | -1x | -1.06x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.41x | 0x | 0x | 0x | 0x | 0x | 0.21x |
| Capitalization / Revenue | 35.4x | 21.7x | 9.36x | 56.7x | - | - | - | - |
| EV / Revenue | 0x | 0x | 0x | 0x | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.92x | -1.05x | -0.77x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -74.4 | -76.96 | -12.64 | -4.98 | -2.14 | -0.55 | -0.4 | -0.38 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 0.8 | 0.9 | 0.8394 | 0.1194 | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -13.14 | -14.24 | -7.698 | -9.44 | -11.85 | -9.5 | -8.35 | -11.3 |
| Net income 1 | -12.6 | -13.8 | -6.141 | -8.3 | -11.08 | -9.3 | -10.1 | -11.3 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 158.4719 | 108.4799 | 12.1152 | 2.6950 | 1.3400 | 0.4010 | 0.4010 | 0.4010 |
| Nbr of stocks (in thousands) | 179 | 180 | 649 | 2,509 | 10,086 | 21,765 | - | - |
| Announcement Date | 3/29/22 | 3/31/23 | 3/15/24 | 3/21/25 | 3/31/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.73x | - | - | - | 8.73M | |
| 21.45x | 7.54x | 15.37x | 1.38% | 72.12B | |
| 37.53x | 9.72x | 29.82x | 0.04% | 65.85B | |
| -18.08x | 7.59x | -9.85x | -.--% | 29.28B | |
| -79.5x | 14.86x | -71.64x | -.--% | 27.47B | |
| 33.76x | 6.66x | 17.64x | -.--% | 26.7B | |
| 27.2x | 5.1x | 17.12x | -.--% | 20.06B | |
| 52.91x | 19.58x | 39.65x | 0.29% | 18.22B | |
| 2460.33x | 41.28x | -5047.29x | -.--% | 16.4B | |
| 16.73x | 4.96x | 11.58x | -.--% | 13.4B | |
| Average | 255.16x | 13.03x | -555.29x | 0.19% | 28.95B | |
| Weighted average by Cap. | 153.00x | 11.04x | -277.31x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SNGX Stock
- Valuation Soligenix, Inc.
Select your edition
All financial news and data tailored to specific country editions
